

1

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Yanhong Zhu et al.))) Art Unit: 1646
Serial No. 10/650,110)
Filed: August 26, 2003) Examiner: Not yet assigned)

For: A Method of Treating and Preventing Alzheimer Disease Through Administration

Of Delipidated Protein and Lipoprotein Particles

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August Va. 2004

Matthew L. Collins

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each Non-U.S. Patent cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

John K. McDonald, Ph.D.

Reg. No. 42,830

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500

Our Docket: 13131-0292 (44378/287574)

ATLLIB02 165183.1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 9

Cor	mplete if Known
Application Number	10/650,110
Filing Date	August 26, 2003 °
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

				U.S. PATENT DOCUMENT	S	
		U.S. Patent D			Date of Publication of	Pages, Columns, Lines, Where
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
muais	1	3,647,624	1	Evenson	03-07-1972	
	2	3,958,939		Jones	05-25-1976	
	3	3,983,008		Shinozaki et al.	09-28-1976	
	4	3,989,466		Pan	11-02-1976	
	5	4,025,423		Stonner et al.	05-24-1977	
	6	4,103,685		Lupien et al.	08-01-1978	
	7	4,124,509		Iijima et al.	11-07-1978	
	8	4,234,317		Lucas et al.	11-18-1980	
	9	4,235,602		Meyer et al.	11-25-1980	
	10	4,258,010	-	Rozsa et al.	03-24-1981	
,	11	4,350,156		Malchesky et al.	09-21-1982	
	12	4,391,711		Jackson et al.	07-05-1983	
	13	4,399,217		Holmquist et al.	08-16-1983	
	14	4,402,940		Nose et al.	09-16-1983	_
	15	4,435,289		Breslau	03-06-1984	
	16	4,463,988		Bouck et al.	08-07-1984	
	17	4,481,189		Prince	11-06-1984	
	18	4,522,809		Adamowicz et al.	06-11-1985	
	19	4,540,401		Marten	09-10-1985	
	20	4,540,573		Neurath et al.	09-10-1985	
	21	4,591,505		Prince	05-27-1986	
	22	4,613,501		Horowitz	09-23-1986	
	23	4,615,886		Purcell et al.	10-07-1986	
	24	4,643,718		Marten	02-17-1987	
	25	4,645,512		Johns	02-24-1987	
	26	4,647,280		Maaskant et al.	03-03-1987	
	27	4,648,974		Rosskopf et al.	03-10-1987	
	28	4,668,398		Silvis	05-26-1987	
	29	4,671,909		Torobin	09-09-1987	
	30	4,676,905		Nagao et al.	06-30-1987	
	31	4,677,057		Curtiss et al.	06-30-1987	
	32	4,680,320		Uku et al.	07-14-1987	
	33	4,696,670		Ohnishi et al.	09-29-1987	
	34	4,775,483		Mookerjea et al.	10-04-1988	
	35	4,832,034		Pizziconi et al.	05-23-1989	
	36	4,836,928		Aoyagi et al.	06-06-1989	
	37	4,879,037		Utzinger	11-07-1989	

Examiner Signature	Date Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2 of 9

Cor	mplete if Known
Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

				U.S. PATENT DOCUMENT	rs	
Examiner Initials	Cite No.1	U.S. Patent	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
11111013	38	4,895,558		Cham	01-23-1990	
	39	4,908,354		Seidel et al.	03-13-1990	
	40	4,909,940		Horowitz et al.	03-20-1990	
	41	4,909,942		Sato et al.	03-20-1990	
	42	4,923,439		Seidel et al.	05-08-1990	
	43	4,935,204		Seidel et al.	06-19-1990	
	44	4,966,709		Nose et al.	10-30-1990	
	45	4,970,144		Fareed et al.	11-13-1990	
	46	5,026,479		Bikson et al.	06-25-1991	
	47	5,080,796		Nose et al.	01-14-1992	
	48	5,089,602		Isliker et al.	02-18-1992	
	49	5,112,956		Tang et al.	05-12-1992	
	50	5,116,307		Collins	05-26-1992	
	51	5,126,240		Curtiss	03-30-1992	
	52	5,128,318		Levine et al.	07-07-1992	
	53	5,152,743		Gorsuch et al.	10-06-1992	······································
	54	5,187,010		Parham et al.	02-16-1993	
	55	5,203,778		Boehringer	04-20-1993	
	56	5,211,850		Shettigar et al.	05-18-1993	
	57	5,236,644		Parham et al.	08-17-1993	
	58	5,256,767		Salk et al.	10-26-1993	
	59	5,258,149		Parham et al.	11-02-1993	
	60	5,279,540		Davidson	01-18-1994	
	61	5,301,694		Raymond et al.	04-12-1994	
	62	5,354,262		Boehringer et al.	10-11-1994	· · · · · · · · · · · · · · · · · · ·
	63	5,391,143		Kensey	02-21-1995	
	64	5,393,429		Nakayama et al.	02-28-1995	
	65	5,401,415		Rauh et al.	03-28-1995	
	66	5,401,466		Foltz et al.	03-28-1995	
	67	5,418,061		Parham et al.	05-23-1995	
	68	5,419,759		Naficy	05-30-1995	
	69	5,424,068		Filip	06-13-1995	
	70	5,476,715		Otto	12-19-1995	
	71	5,484,396		Naficy	01-16-1996	
	72	5,496,637		Parham et al.	03-05-1996	
	73	5,523,096	-	Okarma et al.	06-04-1996	
	74	5,634,893		Rishton	06-03-1997	
	75	5,637,224		Sirkar et al.	06-10-1997	

ſ			
	Examiner	Date	
	Signature	Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of | 9

Cor	nplete if Known
Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

				U.S. PATENT DOCUMENT		
Examiner	Cite	U.S. Patent Doo	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials	No.1 76	5,652,339	(ij known)	Lerch et al.	07-29-1997	r iguico / ppou
	77	5,679,260		Boos et al.	10-21-1997	
· · ·	78	5,698,432		Oxford	12-16-1997	1
	79			Prevost et al.	01-13-1998	
		5,707,673			02-17-1998	
	80	5,719,194		Mann et al.	04-28-1998	
	81	5,744,038		Cham		
	82	5,753,227		Strahilevitz	05-19-1998	
	83	5,853,725		Salk et al.	12-29-1998	
	84	5,855,782		Falkenhagen et al.	01-05-1999	
	85	5,858,238		McRea et al.	01-12-1999	
	86	5,877,005		Castor	03-02-1999	
	87	5,885,578		Salk et al.	03-23-1999	A STATE OF THE STA
	88	5,895,650		Salk et al.	04-20-1999	
	89	5,911,698		Cham	06-15-1999	
	90	5,916,806		Salk et al.	06-29-1999	
	91	5,919,369		Ash	07-06-1999	5,514
	92	5,928,930		Salk et al.	07-27-1999	
	93	5,948,441		Lenk et al.	09-09-1999	
	94	5,962,322		Kozarsky et al.	10-05-1999	
-	95	5,980,478		Gorsuch et al.	11-09-1999	
	96	6,004,925		Dasseux et al.	12-21-1999	
	97	6,017,543		Salk et al.	01-25-2000	
	98	6,022,333		Kensev	02-28-2000	
	99	6,037,323		Dasseux et al.	03-14-2000	
	100	6,039,946		Strahilevitz	03-21-2000	
	101	6,046,166		Dasseux et al.	04-04-2000	
	102	6,136,321	1.11	Barrett et al.	10-24-2000	
	103	6,139,746		Kopf	10-31-2000	
	103	6,156,727		Garber et al.	12-05-2000	
	104	6,171,373		Park et al.	01-09-2001	
100	106	6,193,891		Kent et al.	02-27-2001	
	107			Strahilevitz	07-24-2001	
		6,264,623		Iverson et al.	10-30-2001	
	108	6,309,550			01-08-2002	
	109	6,337,368		Kobayashi et al.	08-12-2003	
	110	6,605,588		Lees et al.		
	111	6,706,008		Vishnoi et al.	03-16-2004	
	1					

	· · · · · · · · · · · · · · · · · · ·	
Examiner	Date	
Signature	Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 9

Cor	nplete if Known
Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

Cite No.1	Office ³	Foreign Patent D	Ocument Kind Code ⁵		Date of Publication of	Pages, Columns, Lines,	- 1							
	Office3		Kind (oda"	I Name of Patastan as	Cited Decument	I Whore	ı							
112	Office ³	Office ³	Office ³	Office ³	Office ³	Office ³	Office ³	Office ³	Number ⁴	(if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1
	CA	1 271 708		Schweiz Serum & Impfinst	07-17-1990									
113	CN	1189378		Central Blood Ban	08-05-1998	Abstract Only								
				ChangChun CI										
114	DE	29 44 138	A1	Technicon Gmbh	06-11-1981									
115	DE	31 18 072	A1	Heuck	11-25-1982		\Box							
116	DE	32 13 390	A1	Schurek, et al.	10-20-1983									
117	DE	33 10 263	A1		09-27-1984									
118	EP	0 036 283	A2	Davy Mckee Minerals & Metals	09-23-1981									
119	EP	0 267 471	Al	Pennwalt Corporation	05-19-1988		Т							
	1						T							
							T							
							T							
			A			10.0	\top							
							T							
	1					Abstract only	\top							
							T							
							寸							
							T							
							十							
							\top							
							十							
							T							
	 						T							
	-	,					7							
							ヿ							
							ヿ							
							7							
					-		7							
							ヿ							
					 		寸							
							\forall							
	1						\forall							
	ļi						寸							
							7							
							寸							
			-	+	-		\dagger							
· -				+			\dagger							
			L		1	<u> </u>	!_							
	116 117	116 DE 117 DE 118 EP 119 EP 120 FR 121 JP 122 JP 123 SU 124 SU 125 SU 126 WO 127 WO	116 DE 32 13 390 117 DE 33 10 263 118 EP 0 036 283 119 EP 0 267 471 120 FR 2 571 971 121 JP 127104 122 JP 277303 123 SU 1116396 124 SU 1204224 125 SU 1752187 126 WO 88/09345 127 WO 95/03840	116 DE 32 13 390 A1 117 DE 33 10 263 A1 118 EP 0 036 283 A2 119 EP 0 267 471 A1 120 FR 2 571 971 A1 121 JP 127104 122 JP 277303 123 SU 1116396 A 124 SU 1204224 A 125 SU 1752187 A3 126 WO 88/09345 A1 127 WO 95/03840 A1	116 DE 32 13 390 A1 Schurek, et al. 117 DE 33 10 263 A1 Fresenius AG 118 EP 0 036 283 A2 Davy Mckee Minerals & Metals 119 EP 0 267 471 A1 Pennwalt Corporation 120 FR 2 571 971 A1 Haas Thierry 121 JP 127104 Shinriyoushiyo 122 JP 277303 Tenkaidou 123 SU 1116396 A Mosc. Med Inst. Pirog 124 SU 1204224 A Kazan Chem. Tech Inst. 125 SU 1752187 A3 Sigalov 126 WO 88/09345 A1 The Rogosin Institute 127 WO 95/03840 A1 The University of Queensland	116 DE 32 13 390 A1 Schurek, et al. 10-20-1983 117 DE 33 10 263 A1 Fresenius AG 09-27-1984 118 EP 0 036 283 A2 Davy Mckee Minerals & 09-23-1981 119 EP 0 267 471 A1 Pennwalt Corporation 05-19-1988 120 FR 2 571 971 A1 Haas Thierry 04-25-1986 121 JP 127104 Shinriyoushiyo 01-10-1980 122 JP 277303 Tenkaidou 10-26-1993 123 SU 1116396 A Mosc. Med Inst. Pirog 09-30-1984 124 SU 1204224 A Kazan Chem. Tech Inst. 01-15-1986 125 SU 1752187 A3 Sigalov 07-30-1992 126 WO 88/09345 A1 The Rogosin Institute 12-01-1988 127 WO 95/03840 A1 The University of Queensland 02-09-1995	116 DE 32 13 390							

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/650,110 **Filing Date** August 26, 2003 INFORMATION DISCLOSURE First Named Inventor Yanhong Zhu STATEMENT BY APPLICANT Group Art Unit 1646 (use as many sheets as necessary Not yet Assigned **Examiner Name** 13131-0292 (44378/287574) of 9 Attorney Docket Number Sheet 5

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	129	Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100. (1983)	
	130	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing	
		Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	131	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles,	
		76 (14), 6919-6928. (July 2002)	
	132	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with	
		Coronary Heart Disease, 2670-2676. (December 1, 2000)	
	133	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human	
		Plasma, 15, 1419-1423. (1995)	
	134	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
	135	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in	
		Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	136	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in	
		the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
	137	Barrans et al., Biochimica et Biophysica Acta, Pre-β HDL: Structure and Metabolism, 1300, 73-85. (1996)	
	138	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human	
		serum , 14, 119-125. (abstract only) (June 1981)	
	139	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as	
		Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
	140	Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17,	
		176-181. (1976)	
	141	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of a - and β -Lipoproteins as a Result of Plasma	
		Delipidation, 22, 305-309. (1976)	

Examiner	Date	
Signature	Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/650,110 August 26, 2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Yanhong Zhu STATEMENT BY APPLICANT Group Art Unit 1646 (use as many sheets as necessary **Examiner Name** Not yet Assigned 13131-0292 (44378/287574) 9 Attorney Docket Number Sheet | 6 of |

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
-	142	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	
	143	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	144	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	145	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid	
		Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
	146	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic	
		Patterns, 11, 61-70. (1996)	
	147	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents	
		Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
	148	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	149	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by	
		Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	150	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49,	
		109-113. (1973)	
	151	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and	1
		Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	152	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by	\dagger
		Capillary Electrophoresis, 14 (7), 100-109. (1996)	
	153	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using	
		the duck hepatitis B model , 22, 119-130. (abstract only) (June 1996)	
	154	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by	
		Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

Examiner	Date	
Signature	Considered	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/650,110 Filing Date August 26, 2003 INFORMATION DISCLOSURE First Named Inventor Yanhong Zhu STATEMENT BY APPLICANT Group Art Unit 1646 (use as many sheets as necessary Examiner Name Not yet Assigned 13131-0292 (44378/287574) Attorney Docket Number Sheet 7 of 9

	τ	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	т—
Examiner Initials	Cite No. ¹	include name of the author (in CAPTIAL LETTERS), title of the article (which appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	155	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH:	
		First Clinical Application of the HELP System, 65, 161-168. (1987)	
	156	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose	
		Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	
	157	Feinstone, et al., Infection and Immunity, Inactivation of Hepatits B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-	
		821. (August 1983)	
	158	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68.	
		(1968)	
	159	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28.	
		(1994)	
	160	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as	
		Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	161	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High	
		Density Lipoproteins, 420, 342-349. (1976)	
	162	Klimov, et al., Kardologiia, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized	
		Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)	
	163	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid	
		Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
	164	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in	
		Hypercholesteraemic Chickens after Treatment with a Newly Developed Extracorpreal Lipid Elimination, (May 13, 1992)	
	165	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in	
		Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	166	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-	
		Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	167	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote	
		Cellular Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)	

Examiner Signature	Date Considered	
0.5	Considered	

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

			Cor	nplete if Known
Substitute	for Form 1449	D/A/PTO	Application Number	10/650,110
	INICOD	MATION DISCLOSURE	Filing Date	August 26, 2003
INFORMATION DISCLOSURE			First Named Inventor	Yanhong Zhu
	STATE	MENT BY APPLICANT	Group Art Unit	1646
(use as many sheets as necessary		(use as many sheets as necessary	Examiner Name	Not yet Assigned
Shoot	8	of 9	Attorney Docket Number	13131-0292 (44378/287574)

<u> </u>	,	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	168	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
	169	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain	
	<u> </u>	Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
	170	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune	
		response to the virus, 48, 517-521. (1997)	
	171	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic	
	:	Method for the Determination of Apolopoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
	172	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When	
		Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
	173	Paterno et al., Department of Clinical and Experimental Medicine, Reconstituted High-Density Lipoprotein Exhibits	
		Neuroprotection in Two Rat Models of Stroke. (December 29, 2003)	
	174	Robern et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of	
		High Density Lipoproteins, 38, 437-439. (1982)	
	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in	
		Plasma or Serum, 13, 769-772. (1967)	
	176	Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the	
		Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum	
		Lipoproteins, 44, 576-588. (1971)	
	177	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density	ļ
		Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
	178	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human	
		Mononuclear Leukocytes, 20, 413-416. (1979)	
	179	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35,	
		41-49. (1980)	

Examiner Date Signature Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

August 26, 2003

Yanhong Zhu

1646

Approved for use through 10/31/2002 OMB 0651-0030

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

First Named Inventor

Filing Date

Group Art Unit

Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/650,110

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Examiner Name Not yet Assigned 13131-0292 (44378/287574) Attorney Docket Number Sheet | 9 of 9

	-	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	180	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1,	
		1208-1211. (1975)	
 	181	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic,	
		Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)	
	182	Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein , 875 (2), 183-194.	
		(February 12, 1986)	
	183	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol	
		extraction, 24, 666-669. (1983)	
	184	Wormser, Henry, PSC3110 - Fall Semester 2002, Lipids.	
	185	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial	
		Hypercholesterolemia, 5, 613-622. (1985)	
	186	Zhang et al., Journal of Lipid Research, Characterization of phospholipids in a pre-alpha HDL: Selective Phospholipid Efflux	
		with Apolipoprotein A-I , 39, 1601-1607. (1998)	
·-··			
	-		
			
	-		
	-		
	1		
Examiner			
Signature		Date Considered	